Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.
Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R. · 2020
Read Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. by Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7164518.txt.
Description
Zhang and co-authors determine the crystal structure of the SARS-CoV-2 main protease and improve a drug that blocks it, in Science. The protease cuts long viral polyproteins into working pieces, making it one of the best-characterised drug targets among coronaviruses. Without it, the virus cannot assemble its machinery.
They solved the enzyme's structure by X-ray crystallography and refined an alpha-ketoamide inhibitor into a potent lead compound. Structures of the inhibitor bound to the protease, at 1.95 and 2.20 angstrom resolution, show exactly how it grips the active site. The work lays a concrete basis for developing anticoronavirus drugs aimed at this enzyme.
Catalog record
| CREATOR | Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |